第 21 回腸内細菌学会

71

海外特別講 演

海外特別講演
Christian Jobin, Ph.D
Professor of Medicine,
Program leader, Cancer Microbiota and Host Response,
University of Florida, USABiosketch
Dr. Christian Jobin received his PhD in Immunology/Microbiology from Université Laval (Quebec, Canada) in
1994.

He did a post-doctoral fellowship at the University of North Carolina Chapel Hill working on bacteria

host interaction in the intestine.
of Florida Gainesville.

He is currently a Gatorade Trust Professor of Medicine at the University

Dr. Jobin’s research focuses on establishing mechanisms controlling host-bacteria inter-action in the intestine. His laboratory is especially interested in the functional impact of bacteria in intestinal
injury repair, inflammation and colorectal cancer.

Using genetically engineered mice and zebrafish, germ-freeand gnotobiotic technology in combination with microbial genomics, he studies the role of bacteria in intestinal homeostasis and disease states. He has published over 140 scientific papers (Science, Nature, Immunity, J.
Exp. Med., Gastroenterology) and presented his work at various national and international scientific meetings.
His research, supported by the National Institute of Health has led to numerous awards and honours (MucosalImmunology Society Award, American Gastroenterological Association Fiterman Young Investigator BasicResearch Award, UF Senior Faculty Excellence in Research Award). Dr. Jobin has served on several study
sections including American Cancer Society, CCFA Fellowship and Career Awards, NIH tumor microenvironment and he is currently serving on the Gastrointestinal Mucosal Pathobiology study section (GMPB-permanentmember).

72

腸内細菌学雑誌

31 巻 2 号

2017

The complex impact of intestinal microbiota in cancer
Christian Jobin
Professor of Medicine,Program leader, Cancer Microbiota and Host Response,University of Florida, USAThe microbiota, particularly the intestinal biota, plays a central role in host physiology and thecomposition and activity of this consortium of microorganisms is directly influenced by known cancer risk factors such as lifestyle, diet and inflammation. Specifically, inflammation represents a condition known to alter the microbial composition and biological activities. Although single organism
such as adherent-invasive E. coli could promote development of colitis-associated colorectal cancer(CRC) in preclinical models, an emerging concept is that polymicrobial interaction is implicatedin human pathology, including inflammatory bowel disease (IBD). We recently demonstrated thatspecific microbial activities are important for development of CRC, with for example the presenceof the pathogenic island pks in certain E. coli B2 group responsible for the synthesis of the secondary metabolite colibactin (Arthur, J.C., et al. (2012), Science 338(6103), 120–123). In addition, we
recently observed a correlation between presence of hydrogen sulfide (H2S)-producing bacteria (HSPB)
and severity of new onset Crohn’s disease (CD) in a pediatric population (Mottawea, W., et al,2016. Nat Commun 7, 1–14). In this lecture, I will discuss the relationship between IBD-associatedbacteria and the development of CRC. Using microbial genomic analysis and gnotobiotic technology, I will present evidence that inflammation is an important factors regulating the carcinogenic
activities of bacteria. In addition, I will discuss the impact of intestinal microbiota on development
and therapeutic response of extra-intestinal cancer. This lecture will highlight the profound modulatory effect of the intestinal microbiota on development of carcinogenesis.